OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
Nantes, France, April 23, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc](https://uknewshour.com/wp-content/uploads/2026/04/ad-hoc-announcement-pursuant-to-art-53-lr-roche-reports-strong-sales-growth-of-6-at-constant-exchange-rates-in-the-first-quarter-of-2026-5-in-chf-due-to-the-significant-appreciation-of-the-swiss.png)
